Compare Phillips 66 (PSX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs State Street SPDR S&P Biotech ETF — how do they compare? Phillips 66 trades at $262 (market cap $103.40B), while State Street SPDR S&P Biotech ETF trades at $159.9. The key difference: Phillips 66 pays a 1.96% dividend while State Street SPDR S&P Biotech ETF pays none, and Phillips 66 is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| PSX | XBI | |
|---|---|---|
Market Cap | $103.40B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $260.78 | $169.55 |
52-Week Low | $126.76 | $93.43 |
Enterprise Value | $119.87B | — |
Dividend Yield | 1.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSX trades at $259.14, up 1.59% today and near its 52-week high, supported by bullish technical signals and strong earnings beats in recent quarters. The stock shows robust profitability with a 24.02% ROE and attractive valuation metrics, including a P/E of 14.79. Recent news highlights momentum from high gas prices and refining efficiency gains, with a dividend of $1.27 payable in September 2026.
Outlook remains positive due to earnings momentum and sector tailwinds, but risks include volatile energy markets and declining revenue trends. Analysts are predominantly bullish with a $242.45 consensus target, though the current price exceeds this, suggesting near-term caution. Institutional buying and stable cash flow growth support long-term potential.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
